Malaria is an infection caused by Plasmodium species endemic to most parts of Africa, South America, East Asia, and parts of Europe and the Middle East. At least 10 to 30 thousand of the 125 million travelers to these areas are infected each year. All visitors to endemic areas should receive counsel...ing on malaria risk, mosquito bite avoidance, and tailored chemoprophylaxis based on their medical histories and travel plans. This activity reviews the evaluation and management of chemoprophylaxis of malaria and highlights the role of the healthcare team in improving care for patients with potential exposure to this condition.
more
This table summarises the drugs used for malaria prevention, including adult and paediatric dosages, timing and special considerations. The medications listed are atovaquone/proguanil, chloroquine, doxycycline, hydroxychloroquine, mefloquine, primaquine and tafenoquine. The guidance covers the use o...f these drugs for primary and terminal prophylaxis, as well as contraindications (e.g. G6PD deficiency, pregnancy, and psychiatric or cardiac conditions) and safety precautions for children and special populations. The aim is to help travellers and healthcare providers reduce the risk of malaria during travel.
Accessed on 27/08/2025.
more
The eEML is a comprehensive, freely accessible online database containing information on essential medicine
The 2022 report reviews the global malaria diagnostics market and technological landscape to support Unitaid’s 2023–2027 strategy for quality malaria case management. The report highlights the stalled progress of malaria control efforts, the gaps in access to diagnostics and the public health im...plications of P. falciparum HRP2/3 gene deletions, which compromise the accuracy of the widely used HRP2-detecting rapid diagnostic tests (RDTs). The report analyses the malaria RDT market, noting supplier diversification, price trends and production shifts resulting from the pandemic. It also addresses the emerging point-of-care G6PD testing market, which is required to ensure the safe radical cure of P. vivax infections. It surveys technological innovation, including digital microscopy, hemozoin tests, nucleic acid detection and biosensors, while emphasising that RDTs and microscopy will remain the mainstay of case management in the near term. The report identifies market shortcomings, access barriers and opportunities to improve malaria case management and diagnostic coverage.
more
This document provides technical guidance for manufacturers seeking World Health Organization (WHO) prequalification of in vitro diagnostic devices (IVDs) for malaria, with a focus on rapid diagnostic tests (RDTs) for symptomatic patients. It summarises the minimum performance requirements, includin...g analytical and clinical performance standards, and emphasises considerations relating to diverse specimen types, testing environments and user populations in low- and middle-income countries. The guidance is aligned with the criteria and prequalification processes of the WHO Global Malaria Programme, while clarifying that demonstration of clinical utility is outside the scope of prequalification.
more
Antimalarial chemotherapy is crucial for reducing morbidity, mortality, and drug resistance, and is the cornerstone of malaria control. Existing antimalarial drugs act at different stages of the parasite’s life cycle. These drugs range from classic agents such as chloroquine and quinine to newer a...rtemisinin derivatives. They include tissue schizonticides, blood schizonticides, gametocytocides, and sporontocides. Artemisinin and its derivatives are the most effective and fastest-acting treatment against drug-resistant Plasmodium falciparum, achieving rapid parasite clearance and reducing transmission potential. Other key drugs include mefloquine, halofantrine, proguanil, sulfadoxine–pyrimethamine, atovaquone–proguanil, tetracyclines, clindamycin and azithromycin. Each of these drugs has a specific mechanism of action, pharmacokinetics, efficacy, safety profile and contraindications. Rational drug combinations and adherence to national treatment guidelines are essential for managing resistance, ensuring safety in vulnerable populations such as children and pregnant women, and optimising therapeutic outcomes in cases of both uncomplicated and severe malaria.
more
Combination therapy is a cornerstone of modern malaria treatment, particularly in the context of widespread multidrug resistance. Using two or more antimalarial drugs with different mechanisms simultaneously enhances efficacy, shortens treatment duration, improves compliance and delays the developme...nt of resistance. Artemisinin-based combination therapies (ACTs), such as artemether–lumefantrine, artesunate–amodiaquine and artesunate–sulfadoxine/pyrimethamine, are highly effective in rapidly clearing parasites and reducing gametocyte carriage. They are also generally well tolerated. Non-artemisinin combinations, quinine-based regimens and novel combinations (e.g. piperaquine–dihydroartemisinin) offer alternative therapeutic options, although clinical experience with these remains limited. Although ACTs are the preferred first-line treatment, factors such as cost, local drug resistance patterns, safety during pregnancy and paediatric use must inform implementation and policy decisions.
more
The annual bulletin of the Mekong Malaria Elimination (MME) programme is a yearly report that reviews ongoing efforts to combat multidrug resistance and eliminate malaria in the 6 countries of the Greater Mekong subregion (GMS): Cambodia, China (Yunnan province), Lao People's Democratic Republic, My...anmar, Thailand and Viet Nam.
more
The Mekong Malaria Elimination (MME) programme is an initiative aimed at supporting Greater Mekong Subregion (GMS) countries – Cambodia, Lao People's Democratic Republic, Myanmar, Thailand, Viet Nam, and Yunnan (China) – in achieving the goal of malaria elimination by 2030. Data for this epidemi...ological summary were compiled from country reports. Between July and September 2024, 48 115 malaria cases were reported. During that period, GMS countries recorded 44% fewer cases, with P. falciparum + mixed and P. vivax cases declining by 81% and 36%, respectively. Meanwhile, testing declined by 25% when compared to the same period in 2023.
more
This document provides technical guidance for manufacturers seeking World Health Organization (WHO) prequalification of in vitro diagnostic devices (IVDs) for malaria, with a focus on rapid diagnostic tests (RDTs) for symptomatic patients. It summarises the minimum performance requirements, includin...g analytical and clinical performance standards, and emphasises considerations relating to diverse specimen types, testing environments and user populations in low- and middle-income countries. The guidance is aligned with the criteria and prequalification processes of the WHO Global Malaria Programme, while clarifying that demonstration of clinical utility is outside the scope of prequalification.
more
Antimicrobial resistance (AMR) and malaria remain significant public health challenges in the WHO Eastern Mediterranean Region (EMR). In 2021, the region reported 1.7 million sepsis-related deaths, with 373,000 associated with bacterial AMR. High antibiotic consumption, particularly in high-income c...ountries, combined with rising usage in middle-income countries, has accelerated the emergence of drug-resistant infections. Malaria management is further complicated by biological threats, including vector insecticide resistance, PFHRP2/3 gene deletions, and antimalarial drug resistance, alongside insufficient trained personnel and limited molecular surveillance capacity. Effective strategies to address these challenges include strengthening regional and cross-border surveillance networks, designating WHO collaborating centers for molecular monitoring, enforcing national treatment policies, and raising public and healthcare provider awareness about rational antimalarial and antibiotic use. These measures, coupled with sustainable funding and enhanced therapeutic efficacy studies, are essential to reduce the development and spread of drug-resistant malaria and improve overall health outcomes in the EMR.
more
Malaria remains a significant public health concern in the SADC region, accounting for 20% of childhood deaths, as well as prompting numerous outpatient visits and hospitalisations. Around three-quarters of the population, including 35 million children under the age of five and 8.5 million pregnant ...women, are at risk. Transmission patterns vary from high and stable in the north to malaria-free in the south, with low, unstable and seasonal zones in between. Although interventions such as indoor residual spraying (IRS), insecticide-treated nets (ITNs/LLINs), intermittent preventive treatment in pregnancy (IPTp), rapid diagnostic tests (RDTs), and artemisinin-based combination therapies (ACTs) have reduced the malaria burden, challenges persist in terms of funding, human resources, surveillance, and cross-border coordination. Achieving malaria elimination in the SADC region requires harmonised regional standards, strengthened surveillance, and improved access to quality treatment and policy prioritisation.
Accessed on 27/08/2025.
more
The 2024 World Malaria Report shows that the malaria burden remains overwhelmingly concentrated in Africa. The continent accounted for 94% of global cases and 95% of malaria-related deaths in 2023. Although the number of malaria cases increased globally from 204 million in 2000 to 246 million in 202...3, the number of deaths declined from 805,000 to 569,000. Children under five are still the most affected group, accounting for 76% of malaria deaths in Africa. A few countries, particularly Nigeria and the Democratic Republic of the Congo, carry the highest burden. Since 2000, Africa has significantly reduced malaria incidence and mortality, averting over 1.7 billion cases and 12 million deaths. Nevertheless, malaria continues to pose a significant health challenge, necessitating ongoing action and investment.
more
In 2022, a total of 6,131 confirmed malaria cases were reported across the EU/EEA. Of these, 5,375 had a known importation status and nearly all (99.8%) were travel-related. Only 13 infections were acquired within Europe, with seven occurring in France, three in Germany, two in Spain and one in Irel...and. A distinct seasonal peak was observed from July to September, reflecting travel to malaria-endemic regions. Notification rates were higher among men than women, with a male-to-female ratio of 2:1. France reported the highest number of cases, followed by Germany, Spain, Italy and Belgium. After dropping sharply in 2020 due to travel restrictions imposed during the pandemic, overall notification rates increased again in 2021 and 2022, reaching 0.8 cases per 100,000 people. These findings emphasise that malaria in Europe is predominantly an imported disease closely linked to international travel, with sporadic local transmission being rare.
more
En 2024, le Cap-Vert et l’Égypte ont été certifiés exempts de paludisme, ce qui prouve qu'il est possible d'éliminer la maladie avec une volonté politique et des ressources adaptées. Cependant, en Afrique, où se concentrent 95 % des cas mondiaux et 97 % des décès (en 2023), les progrès ...stagnent et l’objectif d’élimination d’ici 2030 est menacé. Les principaux obstacles sont le déficit de financement, la résistance aux insecticides et aux médicaments, l'expansion du moustique Anopheles stephensi, le changement climatique, les crises humanitaires et la croissance démographique. Pour inverser la tendance, l’Afrique doit accélérer le déploiement de nouveaux outils (moustiquaires de nouvelle génération, vaccins), renforcer la mobilisation des ressources nationales et diversifier les financements. Une feuille de route de l’Union africaine vise à transformer ces engagements en actions concrètes pour éliminer le paludisme et ses conséquences sanitaires et économiques.
Accessed 27/08/2025.
more
Every two minutes, a child under the age of 5 dies from malaria. Under-five children accounted for 67 per cent of all malaria deaths worldwide in 2018. Most of them occurred in sub-Saharan Africa where an estimated 24 million children were infected with its deadliest form. In addition to being the t...hird-deadliest infectious disease for children, malaria infection and the costs of treatment traps families in a cycle of illness, suffering and poverty.This year’s World Malaria Day is marred by the emergence of the COVID-19 outbreak, which further threatens people’s lives and well-being. Public health officials are taking precautionary and often aggressive measures to limit transmission of this virus, including reductions in social movement, physical distancing, hand-washing and recommending the use of personal protection equipment in high-risk settings. However, while focusing on combating this disease, the world cannot afford to ignore other diseases, such as malaria.
more
Non-Communicable Diseases (NCDs) have emerged as conditions of great public health concern in Kenya accounting for 39% of deaths annually. The Ministry of Health through the Department of Non-Communicable Diseases has adopted the vision of achieving a nation free from preventable burden of NCDs. Fur...ther, the mission of this strategy is to halt and reverse the rising burden of NCDs through effective multisectoral collaboration and partnerships by ensuring Kenyans receive the highest attainable standard of NCD continuum of care that is accessible, affordable, quality, equitable and sustainable thus alleviating suffering, disease and death for their well-being and socio-economic development.
The scope of NCDs covered by this strategy include; cardiovascular diseases, cancer, diabetes, chronic respiratory diseases, mental health conditions, violence and injuries, hemoglobinopathies, haemophilia and other bleeding disorders, auto immune diseases, chronic renal diseases, epilepsy and other neurological disorders, chronic skin conditions and oral diseases and conditions. It equally addresses seven risk factors; tobacco use, harmful use of alcohol, unhealthy diets and toxins, physical inactivity, indoor air pollution, environmental pollutants and toxins and stress.
more
Health in All Policies (HiAP) promotes health and equity. It is based on the recognition that our greatest health challenges for example, non-communicable diseases, health inequities and inequalities, climate change, and spiraling health care costs are highly complex and often linked through the soc...ial determinants of health (SDH). In this context, promoting healthy communities, and in particular health equity across different population groups, requires that we address the social determinants of health, such as public transportation, education access, access to healthy food, economic opportunities, and more. While many public policies work to achieve this, conflicts of interest may arise. Alternatively, unintended impacts of policies are not measured and addressed. This requires innovative solutions, and structures that build channels for dialogue and decision-making that work across traditional government policy siloes. Hence, HiAP could be adopted to ensure commitment from the highest decision makers within government to address the social determinants of health.
more
To guide the provision of quality palliative care services across the African region, the African Palliative Care Association (APCA) has developed a framework of core palliative care competencies that can be used by service providers, educators and other stakeholders to guide programmes development.
The guide helps patients to understand their rights in relation to the care received and provides insights into the common legal and
human rights issues they may encounter, and encourages them to share these with the health care provider for support. This booklet covers key issues that you mig...ht need to understand about ethical care, human rights and legal aspects. It aims to help people with serious illness as they face these issues, and give them guidance on how they can find solutions.
more